IgA nephropathy, also known as Berger's disease, is a kidney disease that occurs when IgA concentration increases in the kidneys, causing inflammation that damages the kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is an orphan disease designated as an orphan indication. This disorder is highly prevalent in countries such as Vietnam and Thailand among others. However, the cumulative cases of this disorder are increasing all across Asia-Pacific.
The rise in IgA nephropathy cases propels market growth as it necessitates an increased focus on R&D and investment in therapeutic solutions. A growing patient population underscores the demand for effective treatments, prompting pharmaceutical companies to innovate and introduce new drug candidates. The expanding market for IgA nephropathy not only attracts heightened R&D expenditure but also stimulates competition among industry players.
Access Full Report @ https://www.databridgemarketresearch.com/reports/indonesia-malaysia-philippines-thailand-and-vietnam-iga-nephropathy-market
Data Bridge Market Research analyzes that the Indonesia, Malaysia, Thailand, Phillipnes, and Vietnam IgA Nephropathy Market is expected to reach USD 42,340.41 thousand by 2034 from USD 15,716.44 thousand in 2023, growing with a CAGR of 10.1% in the forecast period of 2024 to 2034.
Key Findings of the Study
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2034
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Disease Type (Primary IgA Nephropathy and Secondary IgA Nephropathy), Type (Diagnosis and Treatment), Population Type (Adults, Geriatric, and Pediatric), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Diagnostic Centers, Ambulatory Care Centers, Home Healthcare, and Others), Distribution Channel (Retail Sales, Direct Tenders, and Others)
|
|
Countries Covered
|
Indonesia, Malaysia, Thailand, Philippines, and Vietnam
|
|
Market Players Covered
|
Sun Pharmaceutical Industries Ltd (India), Pfizer Inc. (U.S.), Zydus Group (India), Novartis AG (Switzerland), ARKRAY USA, Inc. (U.S.), and Teva Pharmaceutical USA Inc. (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, and regulatory framework
|
Segment Analysis
The Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market is segmented into six notable segments on the basis of disease type, type, population type, route of administration, end user, and distribution channel.
- On the basis of disease type, the market is segmented into primary IgA nephropathy and secondary IgA nephropathy
In 2024, the primary IgA nephropathy segment is expected to dominate the Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market
In 2024, the primary IgA nephropathy segment is expected to dominate the market with a market share of 80.56% due to the introduction of novel drugs coupled with a growing number of clinical trials.
- On the basis of type, the market is segmented into diagnosis and treatment
In 2024, the diagnosis segment is expected to dominate the Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market
In 2024, the diagnosis segment is expected to dominate the market with a market share of 63.90% as the need for early diagnosis of nephropathy for treatment is increasing.
- On the basis of population type, the market is segmented into adults, geriatric, and pediatric. In 2024, adults segment is expected to dominate the market with market share of 84.74%
- On the basis of route of administration, the market is segmented into oral, parenteral, and others. In 2024, oral segment is expected to dominate the market with market share of 68.85%
- On the basis of end user, the market is segmented into hospitals, specialty clinics, ambulatory care centers, diagnostic centers, home healthcare, and others. In 2024, hospitals segment is expected to dominate the market with market share of 58.66%
- On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2024, retail sales segment is expected to dominate the market with market share of 92.88%
Major Players
Data Bridge Market Research analyzes Sun Pharmaceutical Industries Ltd (India), Pfizer Inc. (U.S.), Zydus Group (India), Novartis AG (Switzerland), ARKRAY USA, Inc. (U.S.) as the major market players in Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market.
Market Developments
- In December 2023, Novartis AG performed an investigational iptacopan Phase III study that demonstrated clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G). This development helped the company boost its revenue growth
- In October 2023, Novartis AG’s Phase III clinical study demonstrated a significant proteinuria reduction in patients suffering from IgA nephropathy. The phase III ALIGN study met its primary endpoint, demonstrating the superiority of atrasentan vs. placebo in proteinuria reduction at 36-week interim analysis. IgAN is a progressive kidney disease affecting mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide. This development helped the company boost the market growth
- In October 2021, Teva Pharmaceuticals USA, Inc. announced the launch of FDA-approved generic versions of TRUVADAi and ATRIPLA i tablets for HIV-1 and renal failure. During the COVID-19 pandemic, access to treatment was more essential than ever for those who were immunocompromised and at risk of developing more severe disease. The novel product resulted in an increase in the net sales and distribution of generic drugs across hospitals and diagnostic centers. This launch helped the company boost the market growth
- In February 2021, Zydus Group successfully completed the large-scale enrolment for two Phase III trials of Desidustat. The completion of clinical trials brought a major change in the management of chronic kidney patients with anemia and provided an oral, safer alternative to the available injectable Erythropoietin-Stimulating Agents (ESAs). This development helped the company boost the market growth
- In August 2020, Pfizer Inc. performed the Phase 3b clinical trial of erythropoietin drugs using a specified dosing algorithm in patients with chronic kidney disease on hemodialysis. The clinical trial resulted in the distribution of the drug in hospitals, clinics, and diagnostic centers and a rise in net sales. This development helped the company boost the market growth
Regional Analysis
Geographically, the countries covered in the Indonesia, Malaysia, Thailand, Philippines & Vietnam IgA nephropathy market are Indonesia, Malaysia, Thailand, Philippines, and Vietnam.
For more detailed information about the Indonesia, Malaysia, Thailand, Philippines & Vietnam IgA nephropathy market report, click here – https://www.databridgemarketresearch.com/reports/indonesia-malaysia-philippines-thailand-and-vietnam-iga-nephropathy-market
